"id","uuid:ID","text","description","instanceType","name","label"
"Objective_1","22a547fe-f299-4ec1-82fd-f77c560342a9","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","Main objective","Objective","OBJ1",""
"Objective_2","003335a8-38c4-4e51-a390-cf14585c187a","To document the safety profile of the xanomeline TTS.","Safety","Objective","OBJ2",""
"Objective_3","bd9801cc-17d1-48ac-98c0-8601825d4d65","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","Behaviour","Objective","OBJ3",""
